Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiting Cao

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Lung Cancer (Auckland, N.Z.)|November 11, 2017
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in JapanHiroshi Isobe, Kiyoshi Mori, Koichi Minato, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|September 4, 2024
Cardiovascular death risk in patients with solid tumors: a population-based study in the United StatesShuaijie Gao, Hao Zhu, Xinyu Chang, et al.
Leukemia & Lymphoma|September 21, 2018
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotinChangxia Shao, Jinan Liu, Wei Zhou, et al.
Leukemia & Lymphoma|January 12, 2021
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisEytan M Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, et al.
Journal of Medical Economics|January 21, 2021
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisEytan M Stein, Gaetano Bonifacio, Dominick Latrémouille-Viau, et al.
Clinical Genitourinary Cancer|November 16, 2019
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell CarcinomaXiting Cao, Derek Tang, Barbara Ratto, et al.
Clinical Lung Cancer|July 10, 2018
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung CancerAshwini Arunachalam, Haojie Li, Marisa A Bittoni, et al.
Primary Care Diabetes|December 5, 2023
Associations between physical activity and all-cause and cardiovascular mortality in adults with type 2 diabetes mellitus: A prospective cohort study from NHANES 2007-2018Jie Lu, Xiting Cao, Xinyu Chang, et al.
Leukemia & Lymphoma|March 2, 2021
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updatesEhab L Atallah, Islam Sadek, Rodrigo Maegawa, et al.
Frontiers in Cell and Developmental Biology|October 10, 2022
Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysisJie Lu, Guowei Zheng, Ani Dong, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Lung Cancer (Auckland, N.Z.)|November 11, 2017
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in JapanHiroshi Isobe, Kiyoshi Mori, Koichi Minato, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|September 4, 2024
Cardiovascular death risk in patients with solid tumors: a population-based study in the United StatesShuaijie Gao, Hao Zhu, Xinyu Chang, et al.
Leukemia & Lymphoma|September 21, 2018
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotinChangxia Shao, Jinan Liu, Wei Zhou, et al.
Leukemia & Lymphoma|January 12, 2021
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisEytan M Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, et al.
Journal of Medical Economics|January 21, 2021
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysisEytan M Stein, Gaetano Bonifacio, Dominick Latrémouille-Viau, et al.
Clinical Genitourinary Cancer|November 16, 2019
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell CarcinomaXiting Cao, Derek Tang, Barbara Ratto, et al.
Clinical Lung Cancer|July 10, 2018
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung CancerAshwini Arunachalam, Haojie Li, Marisa A Bittoni, et al.
Primary Care Diabetes|December 5, 2023
Associations between physical activity and all-cause and cardiovascular mortality in adults with type 2 diabetes mellitus: A prospective cohort study from NHANES 2007-2018Jie Lu, Xiting Cao, Xinyu Chang, et al.
Leukemia & Lymphoma|March 2, 2021
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updatesEhab L Atallah, Islam Sadek, Rodrigo Maegawa, et al.
Frontiers in Cell and Developmental Biology|October 10, 2022
Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysisJie Lu, Guowei Zheng, Ani Dong, et al.
Pageof 4